159 Outcomes of thoracic radiotherapy for oligoprogression after a response to Pembrolizumab in patients with advanced Non-Small Cell Lung Cancer
Immunotherapy is the standard of care first line treatment for incurable non-oncogene addicted Non-Small Cell Lung Cancer (NSCLC). There is limited data on thoracic high dose radiotherapy after immunotherapy. Our aim was to assess efficacy and toxicity of radiotherapy, for thoracic oligoprogression after documented response to pembrolizumab in patients with advanced NSCLC.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Dhania Haron, Iain Phillips, Stephen Harrow, Tamasin Evans, Kirsty MacLennan, Sorcha Campbell, Melanie Mackean, Colin Barrie, Mark Stares Tags: Radiotherapy Source Type: research
More News: Addiction | Cancer | Cancer & Oncology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Toxicology